News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
BAKER BROS. ADVISORS LP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.1% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.5% stake in Aravive, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6.6% stake in HOOKIPA Pharma Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 10% stake in Kala Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.4% stake in 2seventy bio, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 9.9% stake in Aeglea BioTherapeutics, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.2% stake in Biomea Fusion, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.2% stake in Cabaletta Bio, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7% stake in Cyteir Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 10% stake in Replimune Group, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.1% stake in Inozyme Pharma, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.2% stake in Kymera Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 9.3% stake in Surrozen, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.5% stake in Nurix Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7% stake in Immatics N.V. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.1% stake in Global Blood Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.5% stake in Aerovate Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.3% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 10% stake in Achilles Therapeutics plc |
| 11/10/2021 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 15.1% stake in Entrada Therapeutics, Inc. |
| 04/12/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.5% stake in Immunocore Holdings plc |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6% stake in Verastem, Inc. |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/05/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2020 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 16% stake in Atreca, Inc. |
| 02/14/2020 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6.8% stake in InflaRx N.V. |
| 09/06/2019 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 16.3% stake in Idera Pharmaceuticals, Inc. |
| 02/13/2019 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 9.9% stake in Clementia Pharmaceuticals Inc. |
| 02/13/2019 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.4% stake in Krystal Biotech, Inc. |
| 02/13/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|
|